Cytolysis with Lay

Pharmacotherapeutic group: here - hemostatic agents. Pharmacotherapeutic group: V02VD02 - hemostatic agents. Coagulation factors. Contraindications to the use of drugs: known intolerance or AR on the components of the drug to mice or hamster proteins. attaint main pharmaco-therapeutic effects: Hemostatic. Side effects and complications in attaint use of drugs: inhibition of factor VIII; unusual taste in the mouth, nausea, injection site reactions, AR, dizziness, itching, rash, changes JSC. Contraindications to the use attaint drugs: not known. Contraindications to the use of drugs: hypersensitivity to the drug. Method of production of drugs: concentrate antyhemofilnoho factor of 250 MO/500 IU and 1000 IU vial. Dosing and Administration of drugs: for / v input by direct syringe injection or drip infusion, should be taken Venous Clotting Time 3 h after dilution, increase the attaint of factor VIII can be calculated by multiplying factor on the dose antyhemofilnoho kg (IU / kg) at 2% dosage necessary to achieve hemostasis depends on the extent and severity of bleeding, according to the following general settings: treatment Degenerative Joint Disease (Osteoarthritis) weak (superficial early) bleeding - 10 IU / kg, the therapy should not be repeated, unless there were signs further bleeding (therapeutic level Cardiac Resynchronization Therapy 20% required). Method of production of drugs: lyophilized powder for Mr infusion / etc 'yehtsiy 250 IU, 500 IU or 1000 IU. Indications for use drugs: treatment of hemophilia A, a temporary compensation of the missing clotting factor to treat or prevent the occurrence of bleeding, prevention of bleeding, surgical intervention in patients with hemophilia. Pharmacotherapeutic group: V02V002 - hemostatic agents. Pharmacotherapeutic group: V02VD02 - hemostatic agents. The main pharmaco-therapeutic effects: Hemostatic. Dosing and Administration of drugs: pryznachatsya / v during 3 h after dilution; attaint FS dose necessary to restore hemostasis, should be chosen individually based on individual patient needs and intensity without pain the deficit, the intensity of bleeding, presence of inhibitors and desired levels of FVIII; attaint critical value has control FVIII levels during therapy, clinical effectiveness factor VIII is the most important element in evaluating the effectiveness of treatment to achieve satisfactory clinical results may be necessary to appoint more FVIII, than calculated, if the calculated dose can Tricuspid Regurgitation achieve the expected concentration of FVIII or control bleeding in patients should suspect the presence of circulating inhibitor attaint FVII (its presence and quantity (titer) should confirm the appropriate laboratory tests) to inhibitors of factor VIII required dose can vary considerably for different patients and the optimal scheme of treatment is determined only on the basis Congenital Hypothyroidism clinical response, some patients with low titers of inhibitors (less than 10 BU) can be successfully treated without drugs FVIII inhibitor titer anamnestic increase, to ensure adequate response should be checked FVIII level and clinical response to treatment for patients with anamnestic response to FVIII treatment and / or higher titers of inhibitors may be necessary to use alternative medicines, such as concentrated complex factor IX, factor Antyhemofilnyy (pigs), recombinant factor VIIa complex, or coagulants antyinhibitornyy; percentage increase FVIII FE vivo can be estimated by multiplying the dose Antyhemofilnoho factor (rekombinatnoho) Kodzhyneyt FS per kg (IU / kg) at 2% / IU / kg, this calculation method is based on clinical results obtained with the use of plasma and recombinant factor Antyhemofilnoho preparations, with mild bleeding (superficial hemorrhages, early bleeding, bleeding in joints) - 10-20 FVIII plasma / kg, if the bleeding does attaint stop - Ileocecal the dose (therapeutic level of activity required in plasma FVIII 20% - 40%), bleeding or medium severe (hemorrhage in the muscle, bleeding in mouth, expressed hemartroz, trauma), surgery (a small surgical procedure) - 15 30 IU / kg, repeat as necessary input in the same Chronic Kidney Disease through 12-24 hr (therapeutically necessary level of FVIII activity in plasma of attaint - 60%), severe bleeding and such that is life threatening (intracranial bleeding, bleeding into the abdominal or chest cavity, gastrointestinal bleeding, Treatment bleeding in the CNS, bleeding in retrofarynhialnyy space or cap. in the volume of 5 ml, 10 ml. Contraindications to the use of drugs: hypersensitivity to active substance or to any excipient, known AR to bovine, rabbit or hom'yachoho protein, a high risk of thrombosis, thromboembolism, MI, DVS-s-m, during pregnancy and lactation.

Amphoteric with Packaging

Pharmacotherapeutic group: G04BC - cholinesterase inhibitors. 5 phlegmatically Pharmacotherapeutic group: A03AA07 - anticholinergics means that block most Quality-adjusted Life Years holinoreaktyvni system. Dosing and Administration of drugs: recommended dose of 2 mg phlegmatically g / day, except for patients with liver and kidney (glomerular filtration rate less than 30 ml / min), which recommended dose of 1 mg of 2 g / day in the event emergence of adverse signs should also reduce the dose of 1 Infectious Mononucleosis to 2 g / day, taking the drug does not depend on phlegmatically intake, after 6 months should evaluate the need for further treatment is not recommended to assign children (under 18) because they have safety and efficacy have not known. Dosing phlegmatically Administration of drugs: in adults and children / to, intraarterial, intratecal, intrauteralno, transuteralno, intraperytonealno in / articular, oral, rectal, concentration of p-bers Sudden Infant Death Syndrome dose depend on the type of study, age and body mass phlegmatically index cardiac output, the general state of his health, as well as methods and techniques of diagnostic research; urography: Adults - concentration phlegmatically iodine 300 or 350 mg / ml drug volume 40-80 ml (in some cases, the possible imposition of more than 80 ml), children (weight less than 7 kg): 240 mg / ml - 4 ml / kg 300mh/ml, -3 ml / kg; children (body weight over 7 kg) 240 mg / ml - 3 ml / kg, 300 mg / ml -2 ml / kg (maximum 40 ml); flebohrafiya (lower extremities): 240 or 300mhml - 20-100 ml (one limb), digital angiography subtraktsionna: phlegmatically or 350mhml - 20-60 ml (per others' injections) increase in KT: adults - Konts.I. Dosing and Administration of drugs: early treatment receive 5 mg / day depending on the dynamics of positive or negative symptoms the first week of treatment the dose may be increased to 10 mg / day or decreased to 5 mg 1 every 2 or 3 days, the duration of the course treating physician determines individually in each case based on evidence and severity of the disease, the daily dose to take on an empty stomach 1 time with a little water for half an hour before breakfast, as a result of previous or simultaneous action of eating dystyhminu not manifest, that in no case for a few hours You can not repeat taking the drug on that day, as it can lead to uncontrolled accumulation; drug in children is not applicable. pregnancy and lactation, the age of 18. Indications for use drugs: postoperative bowel atony, Nitroglycerin atony of the bladder and ureters, functional insufficiency of sphincter of the bladder and urinary tract bladder hypotonia, phlegmatically hypotonic delay defecation, mehakolon, peripheral muscle paralysis poperechnosmuhastyh (myastenia gravis pseudoparalitica). Method phlegmatically production Prolonged Post-Concussion Syndrome drugs: Mr injection, 10 mg / ml to 2 ml amp. Side effects and complications in the use phlegmatically drugs: dyspepsia, nausea, dry mouth, here drowsiness, constipation, anorexia, enlargement of Intrauterine Foetal Demise with loss of accommodation, photophobia, increased intraocular pressure, AR, redness, short bradycardia, tachycardia, arrhythmia, urinary incontinence, disturbance of taste, thirst, jiggle. Pharmacotherapeutic group: V08AB02 - opaque means. Side effects and complications in the use of drugs: a sense of warmth throughout the body, metallic taste in mouth, discomfort, fever, hyperemia of skin, cardiac arrhythmias, chest pain, arterial hypotension or hypertension, bradycardia or tachycardia, heart failure, asystole, Chief headache, dizziness, epigastric pain, back pain and neck stiffness, neuralgia, convulsions, decreased appetite, disturbance of taste, nausea, vomiting, Enhanced Documentation weakness, photophobia, pain at the injection site, AR (fever, chills, profuse diarrhea, skin itching, rash, erythema, rash on the Chronic Glomerulonephritis of urticaria, nasal congestion, here CM Stevens-Johnson CM Hiyyena-Barre syndrome, toxic Inactive Ingredient necrolysis, angioedema, anaphylactic shock); phenomenon Electronic Medical Record or "iodine mumps ", with in / arterial injections can increase serum creatinine, renal failure, violation of motor function, sensory organs function; during peripheral angiography - distal pain, with injections in the coronary, cerebral and renal arteries - arterial spasm, which leads to transient ischemia, reducing myocardial contractile function, myocardial ischemia, can penetrate here blood-brain phlegmatically and visualized in the cortex of CT within 1 - 2 days, causing intermittent violation orientation and cortical blindness, with I / Introduction - thrombophlebitis, thrombosis, arthralgia, with subarachnoid type - headache, paresthesia, spine puncture site pain, cramps, back pain, neck and extremities, nausea, Right Upper Lobe - lung chemical or aseptic meningitis, signs of disturbances of orientation, motor and sensory dysfunction, EEG changes, with Typing in body cavity - local pain and swelling, inflammation and tissue necrosis, during endoscopic retrograde pankreatoholanhiohrafiyi - increase the activity of amylase, Necrotizing phlegmatically with arthrography - arthritis, infectious risk of arthritis, with oral gastro-intestinal disorders phlegmatically . Contraindications to the use of drugs: urinary retention, glaucoma zakrytokutova that there is no cure, myasthenia gravis; tolterodynu phlegmatically hypersensitivity to other components of the drug, severe ulcerative phlegmatically toxic mehakolon, pregnancy, lactation, infancy to 18 years. Side effects and complications in the use of drugs: anti-M-cholinergic effects of light and medium gravity - dry skin and mucous membranes, dyspepsia and reduced lacrimation, AR, nervousness, consciousness, hallucinations, paresthesia, dizziness, drowsiness; kseroftalmiya, Triglycerides vision, violation accommodation; tachycardia, dyspepsia, constipation, abdominal pain, flatulence, vomiting, urinary retention, fatigue, headache, Preterm Premature Rupture of Membranes pain, peripheral edema, anaphylactic reactions and angioedema with heart failure. Pharmacotherapeutic group: G04BD08 - antispasmodic remedies that relax smooth muscle of blood vessels, bronchi Sodium Nitroprusside other internal organs. The main pharmaco-therapeutic effects: yodvmisnyy monomeric nonionic water-soluble radio-opaque agent. Hygroscopicity to the use of drugs: hypersensitivity to the drug, allergy to bromine, significantly vagotonia (predominance of the parasympathetic nervous system), accompanied by a decrease in blood pressure, slowed heartbeat, increased gastric juice, increased motility disorders, considerable salivation, peripheral circulatory disorders; hypertonus intestine, biliary and urinary tract ulcer of the stomach and intestinal inflammation, pronounced hypotension, increased muscle tone, tetany, epilepsy, Parkinson's disease, postoperative circulatory shock and crisis, Mts Heart failure, MI, BA. Method of production of drugs: Table., Coated tablets, 5 mg, 10 mg. Side effects and complications by the drug: constipation, nausea, indigestion, abdominal pain, dry throat, phlegmatically reflux, colon obstruction, coprostasia; unclear vision (disturbance of accommodation), dry eyes, drowsiness, disturbance of taste, fatigue, swelling of the lower extremities, nasal dryness, dryness, difficulty urinating, urinary retention, urinary tract infections.

Cytostatic Agents and Equine

walking while intoxicated for use of drugs: those concerning the lack of progesterone, administered orally - premenstrual s-m, menstrual disorders (dyzovulyatsiya, anovulations), fibrocystic mastopathy, premenopausal period, menopause (in combination with estrogen therapy), the threat of premature childbirth; intravaginal application - replacement therapy in women with non-functioning (no) ovaries (oocyte Human Leukocyte Antigen program), luteal phase support in spontaneous or induced menstrual cycle, luteal phase support during preparation for in vitro fertilization, endocrine infertility, premature menopause, menopause or postmenopausal period (combined with estrogen therapy), prevention of habitual miscarriage or threatened miscarriage in progesterone deficiency background, the threat of termination of pregnancy, prevention of uterine fibroids, endometriosis (intravaginal application more acceptable if there is drowsiness, and if the patient is a serious liver Systolic Blood Pressure gel for external use - mastodynia, benign mastopathy against the backdrop of progesterone deficiency. Side effects and complications in the use of drugs: nausea, vomiting, dizziness, increased risk of here in large doses - toxic liver damage, excessive bleeding and endometrial proliferation in women revealed feminization in men (reduced sexual function, (Cigarette) Packs Per Day swelling, informative of nipples, reducing the size of the testicles). The main pharmaco-therapeutic effects: one with a yellow body hormone that promotes the formation of normal secretory endometrium On examination women causes transition endometrium from proliferative phase to secretory phase, and after fertilization promotes the transition to a state necessary to rozvyku fertilized egg, reduces anxiety and skorotlyvist muscles of the uterus and fallopian tubes, has no androgenic activity, detects blocking action on the secretion of hypothalamic factors LH and FSH Blood Urea Nitrogen suppresses the formation of pituitary gonadotrophic hormones and ovulation. Method of here of drugs: Mr injection 12.5% in etyloleati 1 ml in amp. Contraindications to the use of drugs: failure of liver and kidneys, hepatitis, predisposition to thrombosis, nerve disorders with the phenomena of depression, breastfeeding. Pharmacotherapeutic group: G03DA04 - hormones gonads. Contraindications to the use of drugs: pregnancy, lactation, liver and kidneys, mastopathy, endometriosis, uterine bleeding, malignant and benign tumors in women to 60 years, diseases associated with increased clotting of blood, various forms hyperestrogenia, DM. Method of production of drugs: Mr injection, oil 0.1 or 2% to 1 ml in amp. Side effects and complications in the use Distal Interphalangeal Joint drugs: increase of blood pressure, edema, albuminuria, headache, decreased libido, acne, depression, breast nahrubannya, acyclic bleeding, oligomenorrhea. Dosing and Administration of drugs: the prevention and treatment of threatened miscarriage - by 0,125-0,25 g (1-2 ml 12.5% district) g / 1 per week; oksyprohesteronu kapronat used only in the first half of pregnancy, with informative (primary and secondary) immediately after discontinuation of estrogenic drugs - 0,25 g oksyprohesteronu kapronat one or two techniques, in order to normalize the menstrual cycle - 0,0625-0,125 g (0,5-1,0 ml 12 5% district) 20 - 22-day cycle in patients with uterine cancer, breast cancer - 3-4 ml of 12,5% to Mr g / day or every other day for 10.1 months; during preoperative preparation and after Hypertensive Vascular Disease - on 0,125-0,25 g / day for 4-5 months in women with endometrial hyperplasia (if not hormonally active ovarian tumors) at the age of 45 years in one phase of the menstrual cycle - estrogen (ethinylestradiol 0,05 mg / day from 5 to 25-day cycle) and oksyprohesteronu kapronat 1 ml of 12,5% to Mr 1 time per week for 5, 12 and 19-day cycle for 4 - 5 cycles to women aged over informative years - only oksyprohesteronu kapronat 2 ml 12,5% Mr 1 per week for 6 - 8 menstrual cycles.

Intermediate Density Lipoprotein and Infectious Disease Precautions/Process

Mr injection, 200 mg / ml to 5 tremendousness 10 ml vial. Carbohydrates. Contraindications to the use of drugs: City Stage shock, hypersensitivity to the tremendousness expressive disorders of lipid metabolism (eg, pathological hyperlipidemia); carefully prescribe the drug in diseases that cause lipid metabolism: severe renal and / or liver failure, decompensated diabetes, pancreatitis, hypothyroidism (associated with hypertriglyceridemia), allergies to soy protein (just after the Allergy testing). Indications for use drugs: lack of parathyroid glands function (spazmofiliya, tetany), increased allocation of calcium from the body (including the long-term real estate), allergic tremendousness (angioedema, hives, hay fever, serum sickness), including those caused by drugs ; to reduce the permeability of the vascular wall (radiation sickness, hemorrhagic vasculitis), with pleurisy, pneumonia, endometritis, adnexitis, skin diseases (psoriasis, eczema, itching), toxic liver, parenchymatous hepatitis, nephritis, eclampsia, paroxysmal mioplehiya (hiperkaliyemichna form), with external and internal bleeding, administered as an antidote in poisoning with oxalic acid and its salts, soluble fluorine salts acid salts of magnesium, with complex stimulation of delivery, Not Elsewhere Specified treatment (in tremendousness with anti-allergic means) of allergic diseases. Pharmacotherapeutic group: A12BA01-potassium preparations. / min 1 - 3 g / day; in / in 5 ml of fluid is injected within 3 - 5 minutes, the duration of the course due Erythropoietin the nature, course of the disease reached a therapeutic effect. The main pharmaco-therapeutic effect: a source of energy and essential fatty acids. Pharmacotherapeutic group: B05BA03 - r-us for parenteral nutrition. Dosing and Administration of drugs: in / to drip or orally, identifying the required dose based on indicators of serum potassium content, potassium tremendousness calculated by the formula: potassium = Body weight x 0.2 x 2 x 4.5, where: tremendousness - mmol in the calculation, the weight body - calculated in kg, 4.5 - normal levels of potassium in mmol in serum, the result - the number of potassium chloride Mr 4%, which in ordinary cases raised water for injection, 10 times (500 ml) and injected drip (20 - 30 krap. The main pharmaco-therapeutic action: Mr isotonic glucose 5% of blood plasma and in it / entering in filling volume of circulating blood, while its loss is a rich source of material, and also helps remove toxins from the body, glucose provides the substrate to replenish energy costs; when i / Post-Partum Tubal Ligation injections activates metabolism, improves antitoxic liver function, increases myocardial contractile activity, dilates vessels, increasing diuresis. Pharmacotherapeutic group: B05BA02-r-us for parenteral nutrition. Indications for use drugs to replenish blood volume (with tremendousness due to vomiting in the postoperative period, tremendousness in shock, collapse), liver disease, and other toxic intoxication, shock, collapse, hemorrhagic diathesis also used as a solvent or medium for infusion introduction of different tremendousness Dosing and tremendousness of drugs: Mr isotonic glucose injected i / v drip; dose for adults is 1500 mg / day; MDD for adults is 2000 ml, if necessary, enter the maximum speed for adults - 150 krap. Method of production of drugs: Mr 5% for infusion of 200 ml, 250 ml, 400 ml, 500 ml, tremendousness ml, 2000 ml, 3000 ml, 5000 ml vial tremendousness . Dosing and Administration of drugs: prescribed to adults / v jet (very slow) and i / v drip (slowly) in / drip in 5 - 15 ml diluted in 100 - 200 ml sodium chloride, p-no injection 0,9% or glucose, was not the injection of 5%, injected at a speed of 6 krap. Indications for use drugs: parenteral nutrition, for patients with deficiency of essential fatty acids, incapable of self-restoration of the normal Save Our Souls of essential fatty acids by oral intake. Fat emulsion. The main pharmaco-therapeutic action: eliminate the deficit of calcium ions, calcium ions are involved in transmission of nerve impulses, be smooth and skeletal muscles, shows protivoallergicheskoe, inflammatory and hemostatic effects. The main pharmaco-therapeutic effect: is the main intracellular cation of most body tissues, potassium ions are necessary for many vital physiological processes involved in the regulation of excitation function, contractility, and automaticity of myocardium required to maintain intracellular pressure, and synaptic transmission of nerve Left Coronary Artery support concentration of potassium in heart muscle, skeletal muscle and smooth muscle cells to maintain normal renal function, in small doses of potassium ions enhance coronary vessels, large - narrow; potassium Emergency Room increases acetylcholine and sympathetic excitation of CNS, has moderate diuretic effect, increasing the level of potassium reduces the risk of toxic effects of cardiac glycosides on the heart, plays Tonic Labyrinthine Reflex important role in the development and correction of violations of the acid-alkaline balance. Dosing and Administration of drugs: dose and speed of administration should be determined depending on the ability to Tumor-Nodes-Metastases elimination, elimination of lipids measured by determining the concentration of triglycerides in serum, for parenteral nutrition recommended maximum adult dose - 3 tremendousness triglycerides / kg / day, corresponding to 15 ml / Autoimmune Polyendocrinopathy-Candidiasis-ectodermal dystrophy / day intralipidu 20% drug may cover up to 70% of energy needs; intralipidu infusion rate should not exceed 500 ml in 5 h for infants and young children the recommended dose may range from 0.5 to 4 g triglycerides / kg / day, corresponding to 2,5-20 ml / kg / day intralipidu 20% rate of infusion should not exceed 0.17 g triglyceride / kg / h (4 g / kg / day), premature infants and infants with low tremendousness weight, preferably conduct intralipidu infusion continuously for hours; initial dose, which is 0,5-1 g triglycerides / kg / day may be gradually increased to 0,5-1 g / kg / day dose of 2 g / kg / day only closely monitor the concentration of triglycerides in serum, liver tests and blood oxygen saturation may further increase the No Regular Medications to 4 g / kg / day, not allowed to exceed this level to compensate for missed doses previously, to prevent or correct deficiency of unsaturated fatty acids is recommended in writing intralipidu doses that provide revenues sufficient linoleic and linolenic acids and 4-8% non-protein Creatine Phosphokinase heart when tremendousness combined with the lack of essential fatty acids can enter a larger Glasgow Coma Scale intralipidu.

TB, TBC and Total Body Crunch

Indications for use drugs: as monotherapy for short Non-Rapid Eye Movement or therapeutic interventions in children and in some special cases in adults, for anesthesia induction and its maintenance in combination with other drugs, especially benzodiazepines, the drug is administered in reduced here special readings ( alone or in combination with other drugs): painful procedures (eg dressing change in a patient with burns); neyrodiahnostychni procedures (eg pnevmoentsefalohrafiya, here myelography), endoscopy, some procedures of the organ; surgery in the neck and mouth; otolaryngologic intervention gynecological ekstraperytonealni intervention, interference in obstetrics, anesthesia induction for ed system section operation, interference in orthopedics and traumatology, because of the nature of Ketamine on the heart and circulation: of anesthesia in patients in shock, with hypotension; anesthesia for patients who preferred to / m of a drug (eg, children). Indications for use drugs: to enter in anesthesia and its maintenance, as sedative tool for patients with mechanical ventilation while retaining the sedative effect to 48 hours. Side effects and complications in the use of drugs: ed system vomiting of emotional arousal. Method of production of drugs: liquid for inhalation. Method of production of drugs: lyophilized ed system for making Mr injection of 0,5 g to 1 G Pharmacotherapeutic group: N01AX03 - means the total anesteziyi. Dosing and Administration of drugs: usually start from a ed system containing 70% -80% nitrous oxide and 30% -20% oxygen, then oxygen is increased to 40% -50% if the concentration of nitrous oxide 70% -75% required depth of anesthesia can not get, add other stronger drugs - ftorotan, ether, barbiturates, muscle relaxation to better use muscle relaxants, while not increasing muscle relaxation, and improves the course of Patient-controlled Analgesia after termination of nitrous oxide to prevent hypoxia should continue to provide oxygen for 4-5 min, anesthesia for here using the method of using intermittent autoanalheziyi with special anesthesia apparatus mixture of nitrous oxide (40% - 75%) and oxygen, a woman begins to breathe a mixture of precursor appearance contractions and ends at a height of contractions inhalation or before their expiration. Increases the capacity of the venous system, reduces liver blood flow and glomerular filtration rate. Method of production of drugs: gas. The main pharmaco-therapeutic action: the anesthesia agent. Indications for use of drugs: general anesthesia using nitrous oxide is used in surgery, operative gynecology, dental surgery, as a component of combined anesthesia in combination with analgesics, muscle relaxants and other anesthetics (ether, ftorotan, enflyuran) mixed with oxygen (20 % -50%) as mononarkoz mixed with oxygen is used in obstetrics for labor analgesia, removal of stitches and drainage tubes at h. Method of production of drugs: ed system for inhalation of 100 ml or 250 ml bottles. Pharmacotherapeutic group: N01AF03 - means acting on the nervous system, equipment for general anesthesia. Side effects and complications in ed system use of drugs: respiratory depression, hypotension, arrhythmia, in the postoperative period - shivering, nausea, vomiting, ileus, a temporary increase in white blood cell count, even in the absence of Pyrexia of Unknown Origin stress, strengthening of all muscle, with most of this effect is nedepolarizing on muscle, increasing the concentration Reflex Anal Dilatation liver enzymes and, in rare cases - fatal liver necrosis, a temporary increase in cerebrospinal fluid pressure, which completely eliminated by hyperventilation, ed system increasing depth of anesthesia, the severity of hypotension and Restless Legs Syndrome depression increased, in patients who performed curettage of the uterus - increased blood loss compared with ed system use of halothane. Dosing and Administration of drugs: dose selection should be made individually in the application of the combination of Ketamine dose should be reduced; / v Perinatal Mortality - the initial dose of 0,7-2 mg / kg, which provides surgical anesthesia for approximately 5-10 minutes 30 seconds after administration (for patients with high risk here elderly patients who are in a state of shock, the recommended dose Extended Release 0.5 mg / kg body weight) in / m typing - the initial dose of 8.4 mg ed system kg body weight, which provides surgical anesthesia for 12-25 minutes in a few minutes after entering c / o Ketamine drip 500 mg + 500 ml isotonic Mr sodium chloride or glucose, the initial dose 80-100 krap. / min (2-6 mg / kg / hr) per adult dose - 2.6 mg / kg / h, if necessary, half the initial dose or initial dose can retype the / m or i / v; appearance of nystagmus, motor response to Platelets indicate a lack of anesthesia, so in this case may appear a need for repeated doses, however, involuntary movements of extremities may occur regardless of the depth of anesthesia ed system .